PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency
Shots:
- NICE issued the final draft guidance recommending single-dose gene therapy, Upstaza (eladocagene exuparvovec) for patients aged ≥18mos. with sev. aromatic L-amino acid decarboxylase (AADC) deficiency
- The clinical trial results showed that the therapy improves motor development & these improvements could be long-lasting. The therapy also showed the potential for substantial benefits that were sometimes clearly life-changing
- NICE is expecting to publish its final guidance on eladocagene exuparvovec in April 2023. Upstaza was approved in Great Britain in Nov 2022 & the treatment has been authorized in all 27 EU Member States, Iceland, Norway, Liechtenstein & Northern Ireland
Ref: Nice | Image: PTC Therapeutics
Related News:- PTC Therapeutics to Acquire Censa Pharmaceuticals to Bolster its Rare Disease Portfolio
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
